Equities

Simulations Plus Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Simulations Plus Inc

Actions
TechnologyTechnology
  • Price (USD)12.08
  • Today's Change-0.75 / -5.85%
  • Shares traded471.42k
  • 1 Year change-66.61%
  • Beta1.1546
Data delayed at least 15 minutes, as of Feb 12 2026 20:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

  • Revenue in USD (TTM)78.68m
  • Net income in USD-64.25m
  • Incorporated1996
  • Employees212.00
  • Location
    Simulations Plus Inc800 Park Offices Drive, Suite 401RESEARCH TRIANGLE PARK 27709United StatesUSA
  • Phone+1 (661) 723-7723
  • Fax+1 (661) 723-5524
  • Websitehttps://www.simulations-plus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Electromed Inc66.22m8.20m209.03m177.0027.174.7222.213.160.92950.92957.505.351.294.042.70374,118.7015.999.3318.9911.0478.0476.5612.388.404.66--0.000.0016.9714.5346.3512.62-20.72--
KORU Medical Systems Inc39.07m-3.71m211.23m80.00--12.82--5.41-0.0807-0.08070.84820.35571.433.537.39488,383.00-13.62-19.85-18.41-23.1662.3259.62-9.50-24.861.92--0.0335--17.987.7555.85--25.82--
SANUWAVE Health Inc41.28m-7.04m211.83m46.00------5.13-0.9346-0.93464.68-0.34181.441.7511.07897,456.50-24.53-124.81----78.2671.67-17.06-144.710.8080.09991.14--59.9999.65-21.56--55.47--
CapsoVision Inc13.09m-22.56m226.25m----11.06--17.29-0.4873-0.48730.28260.4368----------------53.13---172.37--4.50--0.00--20.54---76.01------
Orchestra Biomed Holdings Inc2.82m-75.10m229.25m70.00--5.24--81.35-1.82-1.820.06760.77460.03130.657833.7540,257.14-83.39---104.85--93.01---2,665.05--4.72--0.2451---4.42---24.23------
908 Devices Inc57.64m-57.10m238.87m246.00--1.75--4.14-1.61-0.11161.623.770.31231.764.17234,296.80-30.94-18.01-37.82-19.6749.3552.89-99.07-78.453.12--0.00--18.7227.11-98.37--8.96--
Shoulder Innovations Inc41.63m-34.45m252.37m61.00--1.71--6.06-1.91-1.912.247.18----------------76.67---82.75--9.80--0.0913--64.07---50.85------
Simulations Plus Inc78.68m-64.25m258.48m212.00--2.03--3.29-3.20-3.203.906.310.4701--4.28371,113.20-38.39-2.50-40.84-2.6559.6069.96-81.66-7.29----0.00--13.0913.74-750.17--7.57-24.21
Applied Energetics Inc1.15m-13.02m261.43m21.00------226.73-0.0599-0.05990.0053-0.00330.3065--7.7054,908.57-345.27-139.08-454.84-208.3658.5860.61-1,126.59-473.16---------7.78---24.71--51.42--
Quanterix Corp130.20m-95.66m279.33m471.00--0.8876--2.15-2.33-2.333.216.740.30451.444.06276,439.50-22.37-13.18-25.81-14.5351.5356.14-73.47-45.092.31--0.0029--12.3019.36-35.89---20.86--
Trubridge Inc349.88m5.42m279.77m3.20k50.251.558.730.79960.37090.370924.2312.020.8737257.086.17109,338.401.39-0.91071.60-1.0353.1650.131.59-1.141.902.400.4768--0.9464.5256.05--61.10--
Sight Sciences Inc76.05m-46.11m292.38m216.00--4.51--3.84-0.8955-0.89551.471.230.58541.426.71352,092.60-35.49-35.50-39.37-38.5386.8382.63-60.63-94.208.93-76.380.384---1.4727.897.27---10.54--
Evolent Health Inc2.05bn-180.89m297.97m4.50k--0.3538--0.1451-1.57-1.5717.857.550.829--5.17456,456.00-5.17-5.93-6.41-8.0018.4221.07-6.24-7.16--0.1890.5572--30.0930.0434.31---6.87--
Owlet Inc99.64m-42.45m302.56m80.00------3.04-2.75-2.756.08-2.341.523.804.361,245,500.00-60.37-64.44-244.32-331.1152.0644.29-39.68-58.720.9074-2.48----44.529.4054.08---17.23--
Carlsmed Inc-100.00bn-100.00bn303.69m100.00--2.85----------4.01------------------------11.91--0.1265--97.16---31.49------
Data as of Feb 12 2026. Currency figures normalised to Simulations Plus Inc's reporting currency: US Dollar USD

Institutional shareholders

33.99%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20251.06m5.29%
The Vanguard Group, Inc.as of 31 Dec 2025890.41k4.42%
Morgan Stanley & Co. LLCas of 30 Sep 2025868.19k4.31%
First Light Asset Management LLCas of 30 Sep 2025767.76k3.82%
Rockefeller & Co. LLCas of 30 Sep 2025745.92k3.71%
Threadneedle Asset Management Ltd.as of 30 Sep 2025602.47k2.99%
Stephens Investment Management Group LLCas of 31 Dec 2025525.53k2.61%
Tributary Capital Management LLCas of 31 Dec 2025520.86k2.59%
First Eagle Investment Management LLCas of 31 Dec 2025457.16k2.27%
SSgA Funds Management, Inc.as of 30 Sep 2025398.53k1.98%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.